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Abstract
The introduction of the 7-valent pneumococcal conjugate vaccine in children has led to a change in the pattern of pneumococcal sero-
types causing pneumococcal disease. The aim of this study was to compare the clinical presentation and outcome of invasive pneumo-
coccal pneumonia (IPP) in adults between the pre and post-vaccine era. We have conducted an observational study of all adults
hospitalized with IPP, from 1996 to 2001 (pre-vaccine period), and from 2005 to 2009 (post-vaccine period). Incidence, serotype distri-
bution and clinical data were compared between both periods. A total of 653 episodes of IPP were diagnosed. The overall incidence of
IPP increased from 14.2 to 17.9 cases per 100 000 population-year (p 0.003). In the post-vaccine period IPP caused by vaccine serotypes
decreased ()36%; 95% CI, )52 to )15) while IPP caused by non-vaccine serotypes increased (71%; 95% CI, 41–106). IPP in the post-
vaccine period was associated with higher rates of septic shock (19.1% vs. 31.1%, p <0.001). Among patients aged 50–65 years there
was a trend towards a greater proportion of case-fatalities (11.6–23.5%, p 0.087). Independent risk factors for septic shock were IPP
caused by serotype 3 (OR 2.38; 95% CI, 1.16–4.87) and serotype 19A (OR 6.47, 95% CI, 1.55–27). Serotype 1 was associated with a
lower risk of death (OR 0.1; 95% CI, 0.01–0.78). In conclusion, the incidence of IPP in the post-vaccine period has increased in our set-
ting, it is caused mainly by non-vaccine serotypes and it is associated with higher rates of septic shock.
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Introduction
After the implementation of the 7-valent pneumococcal conju-
gate vaccine (PCV7) in the USA signiﬁcant declines in invasive
pneumococcal disease (IPD) due to vaccine serotypes were
reported in children and adults [1–4]. However, due to a
replacement phenomenon, increases of nasopharyngeal coloniza-
tion of children by non-PCV7 serotypes was soon reported
[5,6]. Simultaneously, increases in the incidence of IPD caused by
non-PCV7 serotypes both in children and adults, were also
observed [7,8]. These changes were due mainly to variations in
the incidence of pneumonia, the most common clinical presenta-
tion of IPD, which represents nearly 80% of cases [1,4,6]. In
Spain, PCV7 was introduced in June 2001, and in 2006 it was esti-
mated that about 50% of children had been vaccinated [9]. The
emergence of IPD caused by non-PCV7 serotypes after PCV7
introduction has also been described in our country [8,10,11].
Different studies have shown that capsular pneumococcal
polysaccharide, which is the determinant of the different ser-
otypes, is associated with speciﬁc manifestations of pneumo-
coccal disease [4,12]. In this way, variations in serotype
distributions of IPD may be accompanied by changes in
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clinical presentation. In fact, high rates of empyema associ-
ated with the non-PCV7 serotypes 1 and 3 have been
reported in the last years [13–15].
To our knowledge there are scarce data about the clinical
impact of the emergence of invasive pneumococcal pneumo-
nia (IPP) caused by non-PCV7 serotypes in adults after the
introduction of the PCV7. The aim of our study was to ana-
lyse the differences in the incidence, disease characteristics
and clinical outcome of IPP in adults before and after the
introduction of the PCV7, in an area of Barcelona, Spain.
Patients and Methods
Study population and setting
We performed an observational study of all adults (aged
‡18 years) hospitalized with IPP from January 1996 to Decem-
ber 2001, and from January 2005 to December 2009, in the
University Hospital Vall d’Hebron, a tertiary teaching hospital
in Barcelona that serves a population of 411 227 people [16].
In our hospital, all microbiological strains isolated in sterile
samples are collected systematically. Patients were classiﬁed
into two groups according to the introduction of PCV7 in our
area: pre-vaccine period (1996–2001) and post-vaccine period
(2005–2009). We excluded the interim period (2002–2004)
because of the low initial coverage of the vaccine. In Barcelona,
the estimated vaccine uptake increased from 27% in 2004 [14]
to 36% in 2005 and 47% in 2007 [10]. The study was approved
by the Commission of Medical Ethics of our institution.
Study variables and data collection
The following variables were recorded: (i) sociodemographic
data; (ii) underlying diseases; (iii) immunosuppressive condi-
tions; (iv) severity of the illness at admission (respiratory fail-
ure, septic shock, Pneumonia Severity Index); (v)
microbiological pneumococcal data (serotype and antibiotic
resistance pattern); (vi) antimicrobial therapy and (vii) vari-
ables related to clinical outcome (hospital case-fatality, inten-
sive care unit (ICU) admission, orotracheal intubation
requirement, suppurative lung complications and length of
hospital stay for survivors).
Deﬁnitions
Invasive pneumococcal pneumonia was diagnosed when a
patient had signs and symptoms of an acute-onset lower
respiratory tract infection plus a new pulmonary inﬁltrate on
chest radiography and isolation of S. pneumoniae in blood
and/or pleural ﬂuid cultures [17]. Septic shock was consid-
ered when vasoactive drugs were necessary to obtain appro-
priate arterial pressure values after ﬂuid replacement [18].
Microbiological procedures
Streptococcus pneumoniae isolates were identiﬁed by Gram stain-
ing, optoquin susceptibility, bile solubility testing and latex agglu-
tination testing. Susceptibility of pneumococcal isolates was
tested using the microdilution method, in accordance with the
Clinical and Laboratory Standards Institute procedures. Sero-
typing was performed by capsular swelling (Quellung) reaction
using commercial serogroup and serotype-speciﬁc antiserum at
the Spanish Reference Laboratory (Instituto Carlos III, Madrid),
where all isolates were routinely sent. Serotypes were classiﬁed
into two groups: PCV7 serotypes (serotypes 4, 6B, 9V, 14, 18C,
19F and 23F) and non-PCV7 serotypes (all others). Information
regarding serotype is lacking in 13.5% of the isolates, in most
cases because samples were not sent to the reference centre.
Only 1% of cases were non-typeable pneumococci.
Estimation of the incidence of invasive pneumococcal
pneumonia
We calculated overall and group age incidence rates of IPP
by 100 000 persons-year. In order to make these calculations
we used as denominator the exact number of the population
living in the reference area of the hospital per year according
to the Department of Statistics in Catalunya [19]. Hospital
Vall d’Hebron is the only tertiary hospital in the reference
area and the contribution of other hospitals in the area is
minimal and has not changed during the study period. In
order to avoid some bias related to the reference popula-
tion, we also calculated the incidence of IPP per 1000 adult
admissions in our hospital per year. During the study period
the overall number of admissions per 100 000 of the catch-
ment population has been constant.
To estimate the incidence of IPP due to vaccine or non-
vaccine serotypes, we assumed that the distribution of sero-
types for cases missing serotype information was the same
as the distribution for those cases with serotype information.
Statistical analysis
Statistical analyses were performed using the statistical soft-
ware package SPSS for Windows, version 15.0. Differences in
means of the incidence were tested using the Mantel–Haenszel
test [20]. The absolute risk difference with corresponding 95%
conﬁdence intervals were reported. The chi-square test was
used to compare the distribution of categorical variables and
the Student’s t-test for continuous variables. To asses differ-
ences in disease characteristics between the two periods we
compared overall and age group patients. A univariable and
multivariable logistic regression analysis was performed to
identify variables independently associated with death and sep-
tic shock. Results were considered statistically signiﬁcant if the
two-tailed p value was <0.05.
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Results
Changes in disease burden
During the period of the study 653 episodes of IPP were
diagnosed, nine of them (1.4%) had coexisting meningitis.
The overall incidence of IPP increased signiﬁcantly from 14.2
to 17.9 cases per 100 000 population-year in the post-vac-
cine period. We observed a signiﬁcant decrease in the inci-
dence of IPP due to PCV7 serotypes in the post-vaccine
period ()36%; 95% CI, )52 to )15). In contrast IPP caused
by non-PCV7 serotypes increased signiﬁcantly (71%; 95% CI,
41–106). Non-vaccine serotypes comprised 58% of the iso-
lates in the pre-vaccine period and 78.7% in the post-vaccine
period (p <0.001) (Table 1 and Fig. 1).
Reductions in PCV7 serotypes in the post-vaccine era were
due mostly to a 94% reduction of IPP caused by serotype 6B
TABLE 1. Mean incidence of invasive pneumococcal pneumonia by serotype, age group and time period among adult patients
Pneumococcal disease
Pre-vaccine period Post-vaccine period
Pre vs. post-vaccine period
100 000
population-year 1000 admissions-year
No. of
cases
Cases per
100 000
population/
year
Cases
per 1000
admissions/
year
No. of
cases
Cases per
100 000
population/
year
Cases
per 1000
admissions/
year
Change,
% (95% CI) p value
Change, %
(95% CI) p value
All serotypes
All adults 308 14.2 1.34 345 17.9 1.76 26 (8–47) 0.003 32 (13–53) <0.001
Adults aged 18–50 years 82 8 0.84 127 13.9 1.67 74 (32–130) <0.001 99 (51–153) <0.001
Adults aged 51–65 years 69 8.9 1.33 83 12.1 2.1 35 ()2–86) 0.063 58 (15–118) <0.001
Adults aged >65 years 156 41.8 1.96 135 40.6 1.69 )3 ()33–22) 0.81 )13 ()31–9) 0.214
Conjugate vaccine serotypes
All adults 129 5.9 0.56 73 3.8 0.37 )36 ()52 to )15) 0.002 )33 ()50 to )11) 0.005
Adults aged 18–50 years 45 4.4 0.46 29 3.2 0.38 )28 ()55–15) 0.173 )17 ()48–32) 0.431
Adults aged 51–65 years 19 2.5 0.36 18 2.6 0.47 6 ()44–103) 0.849 25 ()34–138) 0.45
Adults aged >65 years 65 17.7 0.82 26 8.1 0.33 )54 ()70 to )28) <0.001 )60 ()75 to )37) <0.001
Non-conjugate vaccine serotypes
All adults 179 8.2 0.78 272 14.1 1.39 71 (41–106) <0.001 79 (48–116) <0.001
Adults aged 18–50 years 37 3.6 0.38 98 10.7 1.29 198 (104–334) <0.001 241 (133–397) <0.001
Adults aged 51–65 years 51 6.5 0.98 65 9.5 1.64 46 (1–111) 0.042 68 (26–142) 0.006
Adults aged >65 years 91 24.1 1.14 109 32.5 1.37 35 (18–78) 0.036 20 ()9–58) 0.206
Vaccine serotypes: 4, 6B, 9V, 14, 18C, 19F, 23F.
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FIG. 1. Incidence of the invasive pneu-
mococcal pneumonia by years, serotype
groups and age.
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(from 0.9 to 0.1 episodes per 100 000 population-year; 95%
CI, )99 to )56) and a 60% reduction of infections by serotype
9V (from 0.8 to 0.3 episodes per 100 000 population-year;
95% CI, )1 to )84). In non-PCV7 serotypes we found a 125%
increase of IPP caused by serotype 1 (from 1.2 to 2.6 episodes
per 100 000 population-year; 95% CI, 39–263), a 316%
increase of infections by serotype 7F (from 0.5 to 1.9 episodes
per 100 000 population-year; 95% CI, 107–736) and an 874%
increase of infections by serotype 19A (from 0.1 to 1.3 epi-
sodes per 100 000 population-year; 95% CI, 195–3117).
In patients aged 18–50 years, the IPP incidence increased
from 8 to 13.9 cases per 100 000 persons-year (74%; 95%
CI, 32–129), mainly due to an increase of non-PCV7 sero-
types (Table 1).
Sociodemographic variables and underlying diseases
Comparing the two periods, the mean age of the patients
decreased from 62 to 58.5 years (p 0.023). The pattern of
underlying diseases varied depending on the age. In younger
patients (aged between 18 and 50 years) we found a signiﬁ-
cant reduction in the proportion of HIV infections (60.8% vs.
28.7%, p <0.001). On the other hand, patients aged 51–
65 years had greater proportions of chronic medical illness
(43.5% vs. 63.4%, p 0.021) in the post-vaccine period
(Table 2).
Clinical presentation and outcome
The proportion of patients with IPP who presented with
septic shock (19.1% vs. 31.1%, p <0.001) and required ICU
admission (13.7% vs. 21.6%, p 0.011) was signiﬁcantly higher
in the post-vaccine era (Table 2). These specially affected
patients aged 51–65 years, in whom the proportion with
septic shock increased from 17.2% to 35.9% (p 0.015). They
also had a higher PSI score (score ‡IV: 54.5% vs. 76.3%,
p 0.008). The proportion of case-fatalities remained
unchanged in both periods (15.2% vs. 17.1%). However,
among patients aged 51–65 years we found an apparent
trend towards an increase from 11.6% to 23.5% in the post-
vaccine period (p 0.087). The proportion of case-fatalities
showed a possible downward trend in younger patients
(16.9% vs. 8.5%, p 0.111).
After adjustment, the independent risk factor for septic
shock was pneumonia caused by serotype 3 and serotype
19A. Regarding death, high alcohol consumption and haema-
tological cancer were found to be risk factors, and pneumo-
nia caused by serotype 1 a protective factor (Table 3).
Pattern of serotypes
In young adults, the non-vaccine serotypes 1 and 7F were
the most prevalent and caused 35.3% of cases of IPP in the T
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post-vaccine period. Otherwise, serotypes 3, 14 and 19A
were identiﬁed in 31.9% of cases of IPP in patients aged
>50 years, in the same period (Fig. 2). Regarding clinical pre-
sentation, pneumococcal serotypes most often isolated in
cases of septic shock were 3, 19A and 19F (septic shock
developed in 46.7% of infections by serotype 19F, in 40.9%
by serotype 19A and in 38.2% by serotype 3). Interestingly,
none of the patients with IPP caused by serotypes 1 and 5
died.
The proportion of IPP caused by penicillin non-susceptible
strains decreased during the two periods, from 28.3% to
19.7% (p 0.012) (Table S1).
Discussion
In this study we have observed signiﬁcant changes not only
in the incidence but also in the clinical presentation and
severity of IPP in adults after the implementation of the
TABLE 3. Variables associated with (a) septic shock and (b)
death
Univariate
OR (95% CI)
p value Multivariate
OR (95% CI)
p value
(a) Septic shock
Male sex 1.69 (0.13–2.53) 0.007 1.21 (0.72–2.03) 0.472
Age, 18–50 vs.
>50 years
1 (0.68–1.49) 0.528
Post-vaccine period 1.91 (1.3–2.79) 0.001 1.24 (0.74–2.1) 0.414
Smoking 1.08 (0.71–1.78) 0.394
Heavy alcohol
consumption
1.67 (0.98–2.82) 0.004 1.65 (0.9–3.32) 0.106
Chronic lung
disease
1.13 (0.71–1.78) 0.347
Chronic medical
illnessa
0.99 (0.69–1.44) 0.522
Haematological
cancer
0.95 (0.50–1.78) 0.504
Solid cancer 1.7 (1.04–2.79) 0.026 1.67 (0.84–4.87) 0.140
Immunosuppressive
conditionb
1.1 (0.69–1.48) 0.518
Serotype 1 0.78 (0.4–1.53) 0.294
Serotype 3 2.08 (1.16–3.74) 0.012 2.38 (1.16–4.87) 0.018
Serotype 4 0.512 (0.19–1.13) 0.118
Serotype 6B 1.42 (0.48–4.16) 0.351
Serotype 7F 0.89 (0.37–2.12) 0.496
Serotype 8 1.39 (0.66–2.91) 0.246
Serotype 9V 0.37 (00.08–1.65) 0.141
Serotype 14 0.95 (0.49–1.83) 0.511
Serotype 19A 2.79 (0.99–7.87) 0.049 6.47 (1.55–27) 0.010
Serotype 19F 2.22 (0.92–5.32) 0.063 2.46 (0.97–6.21) 0.058
Serotype 23F 0.55 (0.12–2.53) 0.345
Penicillin
susceptibilityc
1.08 (0.7–1.7) 0.402
Cephalosporin
susceptibilityd
1.24 (0.63–2.41) 0.326
(b) Death
Male sex 1.36 (0.85–2.15) 0.119
Age, 18–50 vs.
>50 years
0.58 (3.52–9.58) 0.019 0.61 (0.29–1.31) 0.206
Post-vaccine
period
1.22 (0.85–2.15) 0.212
Smoking 0.77 (0.47–1.27) 0.190
Heavy alcohol
consumption
1.68 (0.92–3.06) 0.066 2.15 (0.05–4.39) 0.036
Chronic lung
disease
0.89 (0.46–1.32) 0.446
Chronic medical
illnessa
1.06 (0.69–1.63) 0.433
Haematological
cancer
1.89 (1.01–3.56) 0.039 3.77 (1.42–10) 0.008
Solid cancer 3.05 (1.82–5.11) <0.001 1.63 (0.62–4.27) 0.317
Immunosuppressive
conditionb
1.96 (1.27–3.03) 0.02 1.08 (0.47–2.48) 0.85
Serotype 1 0.08 (0.01–0.57) <0.001 0.1 (0.01–0.78) 0.028
Serotype 3 1.49 (0.75–2.95) 0.168
Serotype 4 0.69 (0.24–1.99) 0.341
Serotype 6B 1.47 (0.48–4.56) 0.339
Serotype 7F 0.74 (9.25–2.16) 0.397
Serotype 8 0.9 (0.34–2.39) 0.532
Serotype 9V 0.35 (0.05–2.72) 0.260
Serotype 14 1.53 (0.77–3.03) 0.153
Serotype 19A 2.03 (0.63–6.53) 0.191
Serotype 19F 0.77 (0.22–2.64) 0.473
Serotype 23F 0.99 (0.21–4.54) 0.672
Penicillin
susceptibilityc
0.69 (0.43–1.23) 0.092 0.83 (0.43–1.6) 0.58
Cephalosporin
susceptibilityd
0.77 (0.39–1.56) 0.243
aIncludes any of the following: chronic heart disease, chronic lung disease, cere-
brovascular disease, cirrhosis or chronic liver disease, diabetes or chronic renal
insufﬁciency.
bIncludes any of the following: HIV infection, haematological cancer, solid cancer,
solid organ or bone marrow transplant, immunoglobulin deﬁciency, splenectomy
or current immunosuppressive therapy (including systemic steroids).
cIncludes isolates with MIC £0.06 lg/ml.
dIncludes isolates with MIC £0.5 lg/ml.
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FIG. 2. Serotypes causing IPP in the pre and post-vaccine periods by
age groups.
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PCV7 vaccine in children. These clinical changes coincide
with a replacement of the pneumococcal serotypes.
In the United States, after the introduction of the PCV7,
the overall incidence of IPD decreased signiﬁcantly in chil-
dren and adults [1–4]. However, in other geographical areas
these changes have not been so evident. In France, Holland
and Spain, as in our study, the incidence of IPD increased sig-
niﬁcantly in adults [8,14,21,22]. Interestingly, there seems to
be some differences in the burden of IPD in adults in the
United States and Europe. The different vaccine coverage
between USA and Europe could explain in part this discrep-
ancy [1,9,21]. Other factors such as ﬂuctuations of serotypes
or outbreaks of infections in a speciﬁc geographical area may
play a role [8].
The question of why the disease is increasing in younger
adults may be related to the emergence of speciﬁc sero-
types. Non-vaccine serotypes 1, 5 and 7F have a high invasive
potential [23,24], and have been associated with invasive dis-
ease in younger adults [12,25,26]. In our study the emer-
gence of serotypes 1 and 7F could explain the increases in
the incidence of IPP in this age group.
One of the most important ﬁndings of our study is that
the severity of pneumococcal disease has changed in the
post-vaccine period. We have found higher rates of septic
shock and an apparent trend towards greater proportion of
case-fatalities in patients aged 51–65 years, while in younger
people this has tended to decrease. The explanation for
these ﬁndings is probably multifactorial but the emergence of
new serotypes could play a role. Lexau et al.[4] observed an
increase in mortality rates in adults aged 50 years or older,
from 15.7% in 1998 to 19.5% in 2003, and also found that
the non-vaccine serotypes 3, 11A, 19A were independently
associated with higher mortality. Although we have not been
able to ﬁnd a signiﬁcant association between case-fatality and
speciﬁc serotypes, we have observed important differences
depending on the causal serotype. The proportion of case-
fatalities for IPP caused by serotypes 3 and 19A, more preva-
lent in older adults, was 18%, compared with 4% for IPP
caused by serotypes 1 and 7F. The possible downward trend
in proportion of case-fatalities that we have observed in
young adults might be related to the increased incidence of
the serotypes 1 and 7F, which have been associated with
lower mortality rates [12,26–28]. Moreover, in our study
serotype 1 was a protective factor for death in the multivari-
able analysis.
Other factors such as underlying co-morbidity should also
be taken into account. Some studies, as ours, have observed
an increase of chronic medical illness in adults in the post-
vaccine era [4,5]. It has been reported that co-morbidity
could predispose to infections due to serotypes with low
invasive disease potential, which may behave as opportunistic
pathogens causing higher mortality rates [12,25–28]. In this
way, the greater proportion of case-fatalities in patients aged
50–65 years may be also related to the higher rates of co-
morbid conditions in adults in the post-vaccine era.
The increase in the number of patients with IPP who pres-
ent with septic shock is another striking ﬁnding. Pneumonia
caused by serotype 3 has been reported to be associated
with septic shock [18]. We have also observed that sero-
types 3 and specially 19A were associated with the develop-
ment of septic shock. Although 19A is a PCV7-related
serotype, there is evidence of lack of effectiveness of PCV7
against it [29]. In fact, different studies have shown an impor-
tant increase of this serotype after the implementation of
PCV7 [2,4,7]. This serotype has been particularly associated
with severe illness and high mortality [25,27,30]. The impor-
tant emergence of serotype 19A observed in our setting
could explain the increase in the number of cases of IPP with
septic shock.
Our study has some limitations. Because it is not a popu-
lation-based study, the incidence estimates might not be the
most realistic; nevertheless, the results are consistent with
other studies in our area [8,14]. In addition, the hospital is
the only major centre in the reference area, and also the
number of hospital admissions per catchment population has
been constant over the period of study. Secondly, the small
number of episodes caused by some serotypes precluded
analysing their potential correlation with clinical presentation.
Finally, other factors that might also modulate the epidemiol-
ogy and clinical presentation of IPP (e.g. genetic properties of
S. pneumoniae strains, effect of polysaccharide vaccine, viral
co-infections) have not been evaluated in our study.
In conclusion, our study shows an important replacement
of serotypes with an increase in the overall incidence of IPP
in adults since the introduction of the PCV7 vaccine. The
emergence of these new serotypes seems to be associated
with changes in clinical presentation and outcomes of IPP,
especially with higher rates of septic shock. These last ﬁnd-
ings are novel and deserve additional investigation with stud-
ies focused on the clinical and outcomes of IPP in order to
understand the real impact of pneumococcal vaccines, espe-
cially with the introduction of the 13-valent pneumococcal
conjugate vaccine that includes the main new emerging sero-
types.
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